Download MendeleyThe PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner, C.K., Ebrahimi-Nik, H., Iracheta-Vellve, A., Hamel, K.M., Olander, K.E., Davis, T.G.R., McGuire, K.A., Halvorsen, G.T., Avila, O.I., Patel, C.H., Kim, S.Y., Kammula, A.V., Muscato, A.J., Halliwill, K., Geda, P., Klinge, K.L., Xiong, Z., Duggan, R., Mu, L., Yeary, M.D., Patti, J.C., Balon, T.M., Mathew, R., Backus, C., Kennedy, D.E., Chen, A., Longenecker, K., Klahn, J.T., Hrusch, C.L., Krishnan, N., Hutchins, C.W., Dunning, J.P., Bulic, M., Tiwari, P., Colvin, K.J., Chuong, C.L., Kohnle, I.C., Rees, M.G., Boghossian, A., Ronan, M., Roth, J.A., Wu, M.J., Suermondt, J.S.M.T., Knudsen, N.H., Cheruiyot, C.K., Sen, D.R., Griffin, G.K., Golub, T.R., El-Bardeesy, N., Decker, J.H., Yang, Y., Guffroy, M., Fossey, S., Trusk, P., Sun, I.M., Liu, Y., Qiu, W., Sun, Q., Paddock, M.N., Farney, E.P., Matulenko, M.A., Beauregard, C., Frost, J.M., Yates, K.B., Kym, P.R., Manguso, R.T.(2023) Nature 622: 850-862
- PubMed: 37794185
- DOI: https://doi.org/10.1038/s41586-023-06575-7
- Primary Citation of Related Structures:
7UAD - PubMed Abstract:
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance 1,2 . The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity 3-6 . However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable. Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor. AC484 treatment in vitro amplifies the response to interferon and promotes the activation and function of several immune cell subsets. In mouse models of cancer resistant to PD-1 blockade, AC484 monotherapy generates potent anti-tumour immunity. We show that AC484 inflames the tumour microenvironment and promotes natural killer cell and CD8 + T cell function by enhancing JAK-STAT signalling and reducing T cell dysfunction. Inhibitors of PTPN2 and PTPN1 offer a promising new strategy for cancer immunotherapy and are currently being evaluated in patients with advanced solid tumours (ClinicalTrials.gov identifier NCT04777994 ). More broadly, our study shows that small-molecule inhibitors of key intracellular immune regulators can achieve efficacy comparable to or exceeding that of antibody-based immune checkpoint blockade in preclinical models. Finally, to our knowledge, AC484 represents the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy and may pave the way for additional therapeutics that target this important class of enzymes.
Organizational Affiliation:
AbbVie, North Chicago, IL, USA. christina.baumgartner@abbvie.com.
